291 related articles for article (PubMed ID: 27793023)
1. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract][Full Text] [Related]
2. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
3. Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance.
de Cobelli O; Terracciano D; Tagliabue E; Raimondi S; Galasso G; Cioffi A; Cordima G; Musi G; Damiano R; Cantiello F; Detti S; Victor Matei D; Bottero D; Renne G; Ferro M
Urol Oncol; 2015 May; 33(5):201.e1-8. PubMed ID: 25791753
[TBL] [Abstract][Full Text] [Related]
4. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
[TBL] [Abstract][Full Text] [Related]
5. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
6. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
7. Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.
Pichon A; Neuzillet Y; Botto H; Raynaud JP; Radulescu C; Molinié V; Herve JM; Lebret T
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):382-7. PubMed ID: 26439747
[TBL] [Abstract][Full Text] [Related]
8. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
9. Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy: Results from a Contemporary Turkish Patient Cohort.
Tinay I; Aslan G; Kural AR; Özen H; Akdoğan B; Yıldırım A; Ongün Ş; Özkan A; Esen T; Zorlu F; Dillioğlugil Ö; Bekiroglu N; Türkeri L;
Urol Int; 2018; 100(1):43-49. PubMed ID: 29275406
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.
Ferro M; Musi G; Serino A; Cozzi G; Mistretta FA; Costa B; Bianchi R; Cordima G; Luzzago S; Di Trapani E; Tagliabue E; Vartolomei MD; Terracciano D; Cassatella MC; Salvatici M; Conti A; Sandri MT; Cioffi A; Turetti M; Catellani M; Bottero D; Matei DV; Mirone V; de Cobelli O
Urol Int; 2019; 102(1):43-50. PubMed ID: 30408799
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
13. Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.
Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Shakir A; Amigoni N; Rizzetto R; Brunelli M; Migliorini F; Siracusano S; Artibani W
Int Urol Nephrol; 2019 Dec; 51(12):2169-2180. PubMed ID: 31444696
[TBL] [Abstract][Full Text] [Related]
14. Role of Chronic Inflammation as a Predictor of Upstaging/Upgrading in Prostate Cancer: Finding a New Group Eligible for Active Surveillance.
Nowroozi MR; Ayati M; Amini E; Aghamiri SM; Momeni SA; Ohadian Moghadam S; Valizadeh F
Urol J; 2020 Jun; 17(4):370-373. PubMed ID: 31953833
[TBL] [Abstract][Full Text] [Related]
15. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
Verep S; Erdem S; Ozluk Y; Kilicaslan I; Sanli O; Ozcan F
Prostate; 2019 Sep; 79(13):1523-1529. PubMed ID: 31269285
[TBL] [Abstract][Full Text] [Related]
16. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
17. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
18. Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.
Park HJ; Ha YS; Park SY; Kim YT; Lee TY; Kim JH; Lee DH; Kim WJ; Kim IY
Urol Int; 2013; 90(3):301-5. PubMed ID: 23391718
[TBL] [Abstract][Full Text] [Related]
19. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.
Dai B; Qu Y; Kong Y; Ye D; Yao X; Zhang S; Wang C; Zhang H; Yang W
BJU Int; 2012 Dec; 110(11 Pt B):E667-72. PubMed ID: 22974446
[TBL] [Abstract][Full Text] [Related]
20. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]